

Can't find generic Adderall IR? Here are real alternatives your doctor can prescribe, including how they compare in effectiveness, cost, and availability.
If you've been trying to fill a prescription for amphetamine/dextroamphetamine IR (generic Adderall) and keep running into empty shelves, you're not alone. The ongoing shortage has left millions of patients scrambling for their ADHD and narcolepsy medication.
But going without treatment isn't the answer. There are several effective alternatives that your doctor can prescribe — and some of them may actually be easier to find right now.
In this guide, we'll explain what amphetamine/dextroamphetamine IR is, how it works, and walk you through the most common alternatives so you can have an informed conversation with your prescriber.
Amphetamine/dextroamphetamine IR is a central nervous system (CNS) stimulant sold under the brand name Adderall. It's FDA-approved for treating ADHD in children (age 3+) and adults, as well as narcolepsy.
The IR (immediate-release) formulation comes in tablet form and is typically taken 2 to 3 times daily. It starts working within 30 to 60 minutes and lasts about 4 to 6 hours per dose.
It's classified as a DEA Schedule II controlled substance, which means strict rules govern how it's manufactured, prescribed, and dispensed.
Amphetamine/dextroamphetamine works by increasing levels of two key brain chemicals: dopamine and norepinephrine. It does this by blocking their reuptake (so they stay active longer) and promoting their release from nerve cells.
The result is improved focus, attention, and impulse control — the core symptoms of ADHD. For narcolepsy, it helps reduce excessive daytime sleepiness.
Understanding the mechanism matters because it helps explain why some alternatives work similarly and others take a different approach. For a deeper dive, see our article on how amphetamine/dextroamphetamine IR works.
Methylphenidate is the other major stimulant used for ADHD. Brand names include Ritalin, Methylin, and Focalin (dexmethylphenidate).
Like amphetamine/dextroamphetamine, methylphenidate increases dopamine and norepinephrine in the brain — but it does so through a slightly different mechanism. It primarily blocks reuptake rather than promoting release.
Lisdexamfetamine (Vyvanse) is a prodrug of dextroamphetamine, meaning it's inactive until your body converts it into the active drug. This gives it a smoother onset and longer duration of action.
Dextroamphetamine is a single-entity amphetamine — one of the two active components in Adderall. It's available as both IR tablets (Zenzedi) and extended-release capsules (Dexedrine Spansules).
If the IR formulation is unavailable, the extended-release (XR) version may be an option. It contains the same active ingredients but uses a bead-delivery system for longer action.
If stimulants aren't an option for you (due to side effects, substance use history, or other reasons), there are non-stimulant ADHD medications:
Non-stimulants are generally less effective than stimulants for ADHD but are not controlled substances, which means they're easier to prescribe and fill.
Being unable to fill your amphetamine/dextroamphetamine IR prescription is stressful, but you have options. Talk to your doctor about which alternative makes the most sense for your situation.
Before switching medications, it's also worth trying to locate your current prescription using Medfinder — we help patients find amphetamine/dextroamphetamine IR in stock near them.
And if cost is a concern with any of these medications, check out our guide on saving money on amphetamine/dextroamphetamine IR.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.